A Multiple Center, Randomised, Parallel Group, Single-blind Clinical Trial, to Assess the Therapeutic Equivalence in Terms of Efficacy and Safety of Test Product (Levosert) and Reference Product (Mirena®) in Patients With Menorrhagia - Phase III (Therapeutic Equivalence).
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 280
- 主要终点
- Mean change from baseline to Year 1 in the mean menstrual blood loss volume measured using the modified Wyatt pictogram in the two treatment groups
研究概览
简要总结
The primary objective of this study was to compare the efficacy of Test Product (Levosert) vs. Reference Product (Mirena® Bayer-Schering) based on the mean variation of menstrual blood loss volume in women with menorrhagia.
The secondary objectives includes physical and gynaecological examinations, vital signs, clinical laboratory tests including hemoglobin and ferritin measurements, body weight and spontaneously reported adverse events were analysed and compared between Levosert and Mirena® treatment arms. Plasma levels of levonorgestrel (LNG) were also evaluated after various periods of time. The residual amounts of LNG in the devices were finally measured after withdrawal at completion of the study. Plasma levels of LNG and residual amounts of LNG were compared between the two treatment groups. Contraceptive effect of Levosert was estimated by Pearl Index.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Non-pregnant, non-planning pregnancy, non-lactating non-menopausal females at least 18 years of age.
- •Patients with a clinical diagnosis of functional Menorrhagia during the last 6 months.
- •Patients who are eligible and able to participate in the trial and who consent to do so in writing after the purpose and nature of the investigation have been explained to them.
排除标准
- •History of endometrial ablation or dilatation and/or curettage within the 3 months prior to screening
- •Copper - coiled-intrauterine device or LNG releasing IUS use within 2 months prior to screening
- •Abnormal liver function or jaundice
- •Renal insufficiency
- •Other hormonal treatment (sexual steroids),
- •Organic causes of abnormal uterine bleeding (presence of endometrial polyps, submucous myomas of any size, or myometrial myomas > than 3 cm, adenomyosis, atypical hyperplasia, carcinoma)
- •Abnormal uterine morphology
- •Presence of ovarian cyst > 3 cm
- •Lower genital tract infection
- •Current or recurrent PID (present or recurrent pelvis infection (including history of postpartum endometritis, infected miscarriage) during the past 3 months
- •Uncontrolled hypertension
- •Congenital or acquired valvular disease (including corrections with prosthetic valves)
- •Known or suspected pregnancy
- •Known or suspected hormone-dependent tumor
- •BMI > 30
- •Abnormal Pap smear test or other evidence of cervical/endometrial mancy
- •Unexplained amenorrhea
- •Known hypersensitivity to device material and/or Levonorgestrel
研究组 & 干预措施
Levosert-20
Levosert is a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG in a cylindrical-shaped reservoir. The reservoir is mounted on the vertical arm of a T-shaped plastic frame and is covered with a release rate controlling membrane.
干预措施: Levosert-20 (Drug)
Mirena®
Mirena® IUS, Bayer-Schering, a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG.
干预措施: Mirena (Drug)
结局指标
主要结局
Mean change from baseline to Year 1 in the mean menstrual blood loss volume measured using the modified Wyatt pictogram in the two treatment groups
时间窗: 1 year
次要结局
- Comparison of the plasma levels of LNG (Levonorgestrel) in the 2 treatment groups(up to three years)
- Comparison of the residual LNG level in the IUS in the 2 treatment groups(up to three years)
- Mean reduction in menstrual blood loss volume from baseline to intermediate cycles (equivalent to 28-days period)(1 year)